Skip to content

Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease

Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05015244
Acronym
Von2B
Enrollment
5
Registered
2021-08-20
Start date
2019-06-01
Completion date
2023-12-31
Last updated
2022-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von Willebrand Disease, Type 2B

Keywords

VWF, Type 2B von willebrand disease

Brief summary

The working hypothesis is that patients with Von Willebrand Disease-type 2B may have neurological symptoms due to the chronic formation of platelets/Von Willebrand Factor aggregates. Interestingly, several patients present nonspecific neurological symptoms (nystagmus, headaches, memory disorder, …) which may be associated with cerebral microangiopathy and chronic microvessel inflammation secondary to Von Willebrand Disease-type 2B due to chronic exposure to Von Willebrand Factor-platelets complexes.

Detailed description

Investigator will use an extensive series of neuropsychological tests that cover virtually all cognitive domains. A measurement of global cognitive function will be assessed by the Mini Mental State Examination (MMSE). The verbal memory function will be assessed by the Rey Auditory Verbal Learning Test (RAVLT). Visuospatial memory will be administered by the Rey's Complex Figure Test (RCFT). To evaluate speed of mental processes, Stroop test (three subtasks), the Paper and Pencil Memory Scanning Task (four subtasks), the Symbol-Digit Substitution Task will be used. To evaluate attention, the verbal series attention test (VSAT) will be used. To register subjective cognitive failures investigator will administer the Cognitive failures questionnaire (CFQ). The neurological evaluation will be completed with 3T (Tesla) Magnetic Resonance Imaging (MRI) with different MRI sequences including T1 3D SPACE, FLAIR 3D , 3D SWI (Susceptibility weighted imaging) and 2D EPI (Echo Planar Imaging) to address the presence of cerebral small vessel disease. The presence of each of the four MRI markers for cerebral small vessel disease (white matter hyperintensities, lacunes, cerebral microbleeds and perivascular spaces will be addressed.

Interventions

PROCEDURE3T (Tesla) Magnetic Resonance Imaging (MRI)

Neurological evaluation using MRI and neuropsychological tests

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* patients with type 2B disease * neurological signs * signature of inform consent

Exclusion criteria

* contraindication for MRI * Pregnant women * other hemorrhagic disease

Design outcomes

Primary

MeasureTime frameDescription
Rate of cerebral lesions in patients with type 2B diseaseat the inclusionAnalysis of MRI sequences and % of patients with cerebral lesions

Secondary

MeasureTime frameDescription
Verbal memory function evaluationat the inclusionRey Auditory Verbal Learning Test (RAVLT) will be used
Visuospatial memory evaluationat the inclusionRey's Complex Figure Test (RCFT) will be used
Global cognitive function evaluationat the inclusionMini Mental State Examination (MMSE) will be used
Attention evaluationat the inclusionVerbal series attention test (VSAT) will be used
Subjective cognitive failures evaluationat the inclusionCognitive failures questionnaire (CFQ) will be used
Speed of mental processes evaluationat the inclusionStroop test will be used

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026